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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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ABSTRACT
Background: Epilepsy is a chronic disorder or group of chronic disorder in which the indispensable feature is recur-
rence of seizures that are typically unprovoked and usually unpredictable. It is well established that non-adherence to 
antiepileptic drugs may lead to a loss of seizure control. Negative outcomes that may be associated with a loss of 
seizure control include: injury, increase hospitalizations, and decrease in productivity. All of these contribute to 
increased direct and indirect healthcare costs related to epilepsy. Objective: To determine factors leading to non-
compliance with antiepileptic drugs in patients attending a tertiary care hospital. Methods & Results:  In the cross-
sectional study design, total 203 patients, attending neurology outpatient clinic at Department of Neurology Civil Hospi-
tal Karachi, Pakistan, from August, 2010 to February, 2011, with epilepsy were included in the study. Non probability, 
purposive sampling technique was applied. Detailed history was taken from each patient. A structured proforma was 
filled for each patient at the time of visit and note was made of the factors that were responsible for non-compliance. 
Overall mean (±SD) age was 29.1 ±16.9 years (ranging from 6 to 60 years) with Male: Female = 1.9: 1. Most 
common reason for non compliance was high cost of antiepileptic drugs 126 (62.1%) followed by unemployment in 58 
(28.6%) patients, more than one antiepileptic drug in 35 (17.2%) patients, side effects of antiepileptic drugs 19 
(9.4%), freedom free periods from fits 18 (8.9%), deviation from prescription 13 (6.4%) and Non Availability of drugs 
12 (5.9%). Conclusion: In this study, high cost of antiepileptic drugs was the most common reason for non compli-
ance and non-availability of drugs was the least common reason. While unemployment was the second common 
reason for non-compliance
Key Words: Epilepsy, AED, non-compliance, epileptic seizure
INTRODUCTION
In medicine, by the word compliance we mean how 
much a patient behaves in accordance with medical 
advice regarding medication usage, modification of 
lifestyle and follow up visits to the attending physician. 
With respect to drug therapy, compliance is defined as 
the degree of correspondence of the actual dosing 
history with the prescribed drug regimen.1 Epilepsy is 
one those chronic conditions where failure to comply 
with treatment regimen leads to two major conse-
quences: an unfavorable and unwanted health 
outcome for the patient and an increase in health care 
costs. Negative health outcomes include loss of seizure 
control with resultant injury, increased morbidity and 
even death. An increase in health care cost is attributed 
to an increase in physician office visits, emergency 
room care and/or hospitalizations, and a decrease in 
productivity (e.g., missing school and work).2 Studies 
regarding adherence have found four primary factors 
associated with medication non-adherence: patient-
related factors (e.g., socio-economic characteristics, 
and perceptions and beliefs), illness-related factors 
(e.g., severity of illness and frequency of symptoms), 
medication-related factors (e.g., number of daily doses, 
efficacy, and side effects), and physician-related factors 
(e.g., patient-physician relationship).3 Research regard-
ing patient adherence to AEDs has focused largely on 
the impact of the patient physician relationship on 
adherence and potential education programs intended 
to improve adherence. Findings suggest that patients 
tend to be more adherent when physicians have open 
dialogue regarding epilepsy and its treatments and 
when patients are comfortable speaking with their 
physician.4 Due to the paucity of published studies on 
non adherence among patients with epilepsy, this study 
investigates the factors associated with non-adherence 
to AEDs and help in taking possible measures to 
improve antiepileptic drug compliance and prevent 
consequences of uncontrolled seizures. The prevalence 
of epilepsy in Pakistan is about 9.99/1000. Highest 
prevalence is seen in people younger than 30 years of 
age. Higher prevalence is observed in rural population. 
Only 27.5% epileptic persons in urban areas and 1.9% 
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in the rural areas were treated with antiepileptic drugs.3 
When treating epilepsy, the ideal is to achieve complete 
seizure control if compliant; up to 70 per cent of people 
with epilepsy can expect to become seizure free with 
optimal AED therapy.5 
Methods 
This was a cross-sectional study carried out at the 
Department of Neurology, Dow University of Health 
Sciences and Civil Hospital Karachi. All the patients 
with epilepsy attending Neurology outpatient Clinic 
between a period of six months extending from February 
2010 to August 2010 were analyzed and study group 
was selected according to the predetermined inclusion 
and exclusion criteria.  In addition to demographic data, 
factors responsible for non compliance were assessed 
with the help of a structured proforma designed specifi-
cally for this purpose. In this cross-sectional study, a 
total of 203 patients with epilepsy, attending Neurology 
Outpatient Clinic at Civil Hospital Karachi during a 
period of six months extending from August 2010 to 
February 2011 were included. Non probability, purpo-
sive sampling technique was applied. Detailed history 
was taken from each patient. A structured proformas 
was filled for each patient at the time of visit to note the 
factors that were responsible for non-compliance. 
Following is Patient Inclusion Criteria 
• Diagnosis of idiopathic epilepsy irrespective of the
 duration of disease and have been prescribed
 antiepileptic drug by a physician with a proper 
 prescription 
• Patients skipping at least one dose of antiepileptic
 drug in a week. 
• Or missing the dose infrequently but missing
 resulting in seizure.
• Age: 06 to 60 years either male or female. 
Patients with following criteria were excluded
• Patients with symptomatic epilepsy
• Diagnosed case of chronic renal or hepatic failure 
 or any other metabolic disorder that would have
 impaired the concentration of AED. 
• Patients who were given inadequate dosage or
 inadequate instructions by their physicians.
Data was analyzed on SPSS version 14.0. Frequencies 
and percentages were computed for qualitative 
variables, gender, age group, educational status and 
factors leading to non-compliance (e.g high cost, 
unemployment, kept on more than on drug, side 
effects, freedom from fits, deviation from prescription, 
non availability of drugs, personal belief-taboos and 
taking other medicines). Mean and standard deviation 
was computed for quantitative variables like age. Strati-
fication was done on age, gender and education status 
to see the effects on outcome.
Results
A total of 203 diagnosed cases of epilepsy were 
included in this study. Of 203 cases of epilepsy, 133 
(65.5%) patients were male and 70 (34.5%) female 




The mean age of patients attended Department of 
Neurology, Civil Hospital Karachi was 29.1 ±16.9 years 
and their age ranged from 6 years to 60 years. Majority 
83 (40.9%) of cases had age between 5 – 20 years. 
(Figure-1)
Education level of participants was also noted .The 
majority of patients were illiterate 101(49.8%), 82 
(40.4%) participants were educated up to matric, 18 
(8.9%) were intermediate and only 2 (1%) patients 
were graduate. (Table-2)





Most common reason for non compliance was high cost 
of antiepileptic drugs 126 (62.1%). Fifty eight (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antie-
pileptic drugs 19 (9.4%), freedom from fits 18 (8.9%), 
deviation from prescription 13 (6.4%) and Non Avail-
ability of drugs 12 (5.9%) (Table-3)
Factors  n (%)
High Cost 126 (62.1)
Unemployment 58 (28.6)
Kept on more than on drug 35 (17.2)
Side Effects 19 (9.4)
Freedom from fits 18 (8.9)
Deviation from Prescription 13 (6.4)
Non Availability of drugs 12 (5.9)
Personal belief-taboos 11 (5.4)
Taking other medicines 5 (2.5)
In male patients most dominant reason for poor drug 
compliance was unemployment 57 (98.3%), followed 
by high cost 90 (71.4%), freedom from fits 12(66.7%), 
side effects 11 (57.9%) and non availability of drugs 6 
(50%). (Table-4) 
Whereas in female patients the most prominent reason 
for poor drug compliance was personal belief –taboos 7 
(63.6%), followed by taking other medicines for other 
illness 3 (60%), deviation from prescription 8 (61.5%) 
and kept on more than one antiepileptic drug 18 
(51.4%). (Table-4)
When reasons for noncompliance were cross tabulated 
against different age groups, Unemployment (44.8%) 
was found most prominent reason of poor drug compli-
ance in age groups 21-40 and 41-60. Personal belief-
taboos (45.4%) was associated with younger age group 
5-20. (Table-5)
Factors  Age Group (Years)
 05-20 21-40 41-60
High Cost 51 (40.47%) 36 (28.5%) 3 9 
(30.9%)
Non Availability of drugs 4 (33.3%) 5 (41.6%) 
3 (25%)
Personal belief-taboos 5 (45.4%) 2 (18.1%) 
4 (36.3%)
Freedom from fits 5 (27.7%) 7 (38.8%) 
6 (33.3%)
Unemployment 6 (10.3%) 26 (44.8%) 2 6 
(44.8%)
Side Effects 15 (78.9%) 2 (10.5%) 2 
(10.5%)
Taking other medicines 0.0% 0.0% 100.0%
Kept on more than on drug 20 (57.1%) 6 
(17.1%) 9 (25.7%)
Deviation from Prescription 6 (46.1%) 5 
(38.4%) 2 (15.3%)
 
Factors associated to noncompliance were also 
analyzed against education level of patients. Non avail-
ability of antiepileptic drug 9 (75%) was the major 
cause of poor compliance in illiterate patients. Unem-
ployment 30 (51.7%) and high cost 61 (48.4%) were 





Compliance with a prescribed medicine regimen is a 
ubiquitous problem not confined to the treatment of 
asymptomatic conditions. Despite this, the poor compli-
ance in patients with epilepsy is somewhat surprising 
given that patients are aware of the serious conse-
quences in terms of seizures and even death. In this 
context it is important that we look for ways to improve 
epilepsy patients’ adherence to the prescribed medica-
tion as a way of improving outcome. There are many 
factors that influence compliance in people with 
epilepsy but the frequency, type and severity of seizures 
do not in themselves appear to influence compliance 
rates.6 Irregular requests for repeat AED prescriptions, 
lack of response to appropriate therapy and an increase 
in seizure frequency may indicate non-compliance. It is, 
however, difficult to identify all patients who do not 
comply with their AED therapy. Health professionals 
should therefore be alert to the potential for non-
compliance in all patients with epilepsy, enquiring non-
judgementally about medicine taking at each consulta-
tion and being prepared to support patients in complying 
with their treatment. In addition to the diagnosis of 
epilepsy in a considerable number of patients depres-
sive mood changes exist. In those patients rates of 
adherence is reduced and requires special strategies for 
continuous treatment.7 The patients can have poor 
compliance if they do not understand the importance of 
taking their medication, if they experience side effects, 
feel stigmatized by their condition, have difficulty in 
swallowing their medication or have multiple doses.8 
These issues can be multiplied if the patient is on multi-
ple medications for concomitant conditions. Age can 
also be a factor with compliance being particularly poor 
in teenagers.9 Although non-compliance in epilepsy may 
be unintentional, most non-compliance with AEDs is 
intentional and results from conscious choices by 
patients.10 These decisions are based on patients’ 
beliefs about medicines in general that are affected by 
the experience of family and friends, culture, education, 
social circumstances, fears and anxieties and may be 
the result of an incomplete understanding of epilepsy 
and the proposed treatment. The result may be that 
patients are unsure that the benefits of AED treatment 
outweigh the perceived risks of taking medication. 11 In 
this study most common reason for non compliance was 
high cost of antiepileptic drugs (62.1%). (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antiepi-
leptic drugs (9.4%), freedom from fits (8.9%), deviation 
from prescription (6.4%) and Non Availability of drugs 
(5.9%). A survey undertaken by Neurologists (n=661) 
in the USA10 revealed that 71% of patients with 
epilepsy forgot to take their AED (anti-epileptic drug) at 
least once per month and it was evident that the chance 
of a patient missing a dose increased with the number 
of tablets prescribed. Of patients that missed a dose 
45% reported a seizure. Patients taking a larger number 
of tablets/capsules increased their odds of having a 
seizure after a missed dose by 43%. Similar results were 
reported in a recent UK study 12 which revealed that 
59% of epilepsy patients had poor compliance and that 
this was related to an increased frequency of seizures. A 
study in Germany13 measured post-ictal serum levels of 
anti-epileptic medications and confirmed that in at least 
44% of cases the seizure was related to poor compli-
ance. A review of 10,892 epilepsy patients in a USA 
managed care system 14 revealed that poor adherence 
was associated with a 11% increase in hospitalization 
and a 47% increase in emergency admissions and as a 
consequence there was significantly increased health-
care costs. It is evident that if patients’ seizures are not 
controlled by one AED there may be no point changing 
to another if the reason for lack of efficacy is non-
compliance. Studies have investigated a range of inter-
ventions, but improving compliance in chronic condi-
tions such as epilepsy is a complex task.15 Clinical 
guidelines provide detailed recommendations about the 
importance of ongoing counseling, education and 
support for people with epilepsy16, and it is also essen-
tial to ask about practical problems that may reduce 
compliance, including any difficulties in taking the medi-
cine, side-effects or inconvenient AED dosing. The 
number of daily doses is the most consistent predictor of 
noncompliance with AED treatment and an increased 
risk of seizure.10 The aim should be to move towards an 
easy-to-take once daily medication whenever possible. 
Opportunities to simplify the dosage of an AED are 
limited since the majority of these drugs must be taken 
twice or three times daily and the licensed indications of 
some once-daily drugs are limited. 
Conclusion
In this study, high cost of antiepileptic drugs was the 
most common reason for non compliance and non-
availability of drugs was the least common reason. 
While unemployment was the second common reason 
for non-compliance. These findings underscore the 
factors associated with and the impact of non-
adherence in adult patients with epilepsy. Targeted 
epilepsy management programs and communication 
strategies are necessary to improve adherence and to 
avoid the clinical consequences of poor adherence.
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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INTRODUCTION
In medicine, by the word compliance we mean how 
much a patient behaves in accordance with medical 
advice regarding medication usage, modification of 
lifestyle and follow up visits to the attending physician. 
With respect to drug therapy, compliance is defined as 
the degree of correspondence of the actual dosing 
history with the prescribed drug regimen.1 Epilepsy is 
one those chronic conditions where failure to comply 
with treatment regimen leads to two major conse-
quences: an unfavorable and unwanted health 
outcome for the patient and an increase in health care 
costs. Negative health outcomes include loss of seizure 
control with resultant injury, increased morbidity and 
even death. An increase in health care cost is attributed 
to an increase in physician office visits, emergency 
room care and/or hospitalizations, and a decrease in 
productivity (e.g., missing school and work).2 Studies 
regarding adherence have found four primary factors 
associated with medication non-adherence: patient-
related factors (e.g., socio-economic characteristics, 
and perceptions and beliefs), illness-related factors 
(e.g., severity of illness and frequency of symptoms), 
medication-related factors (e.g., number of daily doses, 
efficacy, and side effects), and physician-related factors 
(e.g., patient-physician relationship).3 Research regard-
ing patient adherence to AEDs has focused largely on 
the impact of the patient physician relationship on 
adherence and potential education programs intended 
to improve adherence. Findings suggest that patients 
tend to be more adherent when physicians have open 
dialogue regarding epilepsy and its treatments and 
when patients are comfortable speaking with their 
physician.4 Due to the paucity of published studies on 
non adherence among patients with epilepsy, this study 
investigates the factors associated with non-adherence 
to AEDs and help in taking possible measures to 
improve antiepileptic drug compliance and prevent 
consequences of uncontrolled seizures. The prevalence 
of epilepsy in Pakistan is about 9.99/1000. Highest 
prevalence is seen in people younger than 30 years of 
age. Higher prevalence is observed in rural population. 
Only 27.5% epileptic persons in urban areas and 1.9% 
in the rural areas were treated with antiepileptic drugs.3 
When treating epilepsy, the ideal is to achieve complete 
seizure control if compliant; up to 70 per cent of people 
with epilepsy can expect to become seizure free with 
optimal AED therapy.5 
Methods 
This was a cross-sectional study carried out at the 
Department of Neurology, Dow University of Health 
Sciences and Civil Hospital Karachi. All the patients 
with epilepsy attending Neurology outpatient Clinic 
between a period of six months extending from February 
2010 to August 2010 were analyzed and study group 
was selected according to the predetermined inclusion 
and exclusion criteria.  In addition to demographic data, 
factors responsible for non compliance were assessed 
with the help of a structured proforma designed specifi-
cally for this purpose. In this cross-sectional study, a 
total of 203 patients with epilepsy, attending Neurology 
Outpatient Clinic at Civil Hospital Karachi during a 
period of six months extending from August 2010 to 
February 2011 were included. Non probability, purpo-
sive sampling technique was applied. Detailed history 
was taken from each patient. A structured proformas 
was filled for each patient at the time of visit to note the 
factors that were responsible for non-compliance. 
Following is Patient Inclusion Criteria 
• Diagnosis of idiopathic epilepsy irrespective of the
 duration of disease and have been prescribed
 antiepileptic drug by a physician with a proper 
 prescription 
• Patients skipping at least one dose of antiepileptic
 drug in a week. 
• Or missing the dose infrequently but missing
 resulting in seizure.
• Age: 06 to 60 years either male or female. 
Patients with following criteria were excluded
• Patients with symptomatic epilepsy
• Diagnosed case of chronic renal or hepatic failure 
 or any other metabolic disorder that would have
 impaired the concentration of AED. 
• Patients who were given inadequate dosage or
 inadequate instructions by their physicians.
Data was analyzed on SPSS version 14.0. Frequencies 
and percentages were computed for qualitative 
variables, gender, age group, educational status and 
factors leading to non-compliance (e.g high cost, 
unemployment, kept on more than on drug, side 
effects, freedom from fits, deviation from prescription, 
non availability of drugs, personal belief-taboos and 
taking other medicines). Mean and standard deviation 
was computed for quantitative variables like age. Strati-
fication was done on age, gender and education status 
to see the effects on outcome.
Results
A total of 203 diagnosed cases of epilepsy were 
included in this study. Of 203 cases of epilepsy, 133 
(65.5%) patients were male and 70 (34.5%) female 




The mean age of patients attended Department of 
Neurology, Civil Hospital Karachi was 29.1 ±16.9 years 
and their age ranged from 6 years to 60 years. Majority 
83 (40.9%) of cases had age between 5 – 20 years. 
(Figure-1)
Education level of participants was also noted .The 
majority of patients were illiterate 101(49.8%), 82 
(40.4%) participants were educated up to matric, 18 
(8.9%) were intermediate and only 2 (1%) patients 
were graduate. (Table-2)





Most common reason for non compliance was high cost 
of antiepileptic drugs 126 (62.1%). Fifty eight (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antie-
pileptic drugs 19 (9.4%), freedom from fits 18 (8.9%), 
deviation from prescription 13 (6.4%) and Non Avail-
ability of drugs 12 (5.9%) (Table-3)
Gender n % 
Male 133 65.5 
Female 70 34.5 
Education Level n % 
Illiterate 101 49.8% 
Matric 82 40.4% 
Intermediate 18 8.9% 
Graduation 2 1.0% 
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Factors  n (%)
High Cost 126 (62.1)
Unemployment 58 (28.6)
Kept on more than on drug 35 (17.2)
Side Effects 19 (9.4)
Freedom from fits 18 (8.9)
Deviation from Prescription 13 (6.4)
Non Availability of drugs 12 (5.9)
Personal belief-taboos 11 (5.4)
Taking other medicines 5 (2.5)
In male patients most dominant reason for poor drug 
compliance was unemployment 57 (98.3%), followed 
by high cost 90 (71.4%), freedom from fits 12(66.7%), 
side effects 11 (57.9%) and non availability of drugs 6 
(50%). (Table-4) 
Whereas in female patients the most prominent reason 
for poor drug compliance was personal belief –taboos 7 
(63.6%), followed by taking other medicines for other 
illness 3 (60%), deviation from prescription 8 (61.5%) 
and kept on more than one antiepileptic drug 18 
(51.4%). (Table-4)
When reasons for noncompliance were cross tabulated 
against different age groups, Unemployment (44.8%) 
was found most prominent reason of poor drug compli-
ance in age groups 21-40 and 41-60. Personal belief-
taboos (45.4%) was associated with younger age group 
5-20. (Table-5)
Factors  Age Group (Years)
 05-20 21-40 41-60
High Cost 51 (40.47%) 36 (28.5%) 3 9 
(30.9%)
Non Availability of drugs 4 (33.3%) 5 (41.6%) 
3 (25%)
Personal belief-taboos 5 (45.4%) 2 (18.1%) 
4 (36.3%)
Freedom from fits 5 (27.7%) 7 (38.8%) 
6 (33.3%)
Unemployment 6 (10.3%) 26 (44.8%) 2 6 
(44.8%)
Side Effects 15 (78.9%) 2 (10.5%) 2 
(10.5%)
Taking other medicines 0.0% 0.0% 100.0%
Kept on more than on drug 20 (57.1%) 6 
(17.1%) 9 (25.7%)
Deviation from Prescription 6 (46.1%) 5 
(38.4%) 2 (15.3%)
 
Factors associated to noncompliance were also 
analyzed against education level of patients. Non avail-
ability of antiepileptic drug 9 (75%) was the major 
cause of poor compliance in illiterate patients. Unem-
ployment 30 (51.7%) and high cost 61 (48.4%) were 





Compliance with a prescribed medicine regimen is a 
ubiquitous problem not confined to the treatment of 
asymptomatic conditions. Despite this, the poor compli-
ance in patients with epilepsy is somewhat surprising 
given that patients are aware of the serious conse-
quences in terms of seizures and even death. In this 
context it is important that we look for ways to improve 
epilepsy patients’ adherence to the prescribed medica-
tion as a way of improving outcome. There are many 
factors that influence compliance in people with 
epilepsy but the frequency, type and severity of seizures 
do not in themselves appear to influence compliance 
rates.6 Irregular requests for repeat AED prescriptions, 
lack of response to appropriate therapy and an increase 
in seizure frequency may indicate non-compliance. It is, 
however, difficult to identify all patients who do not 
comply with their AED therapy. Health professionals 
should therefore be alert to the potential for non-
compliance in all patients with epilepsy, enquiring non-
judgementally about medicine taking at each consulta-
tion and being prepared to support patients in complying 
with their treatment. In addition to the diagnosis of 
epilepsy in a considerable number of patients depres-
sive mood changes exist. In those patients rates of 
adherence is reduced and requires special strategies for 
continuous treatment.7 The patients can have poor 
compliance if they do not understand the importance of 
taking their medication, if they experience side effects, 
feel stigmatized by their condition, have difficulty in 
swallowing their medication or have multiple doses.8 
These issues can be multiplied if the patient is on multi-
ple medications for concomitant conditions. Age can 
also be a factor with compliance being particularly poor 
in teenagers.9 Although non-compliance in epilepsy may 
be unintentional, most non-compliance with AEDs is 
intentional and results from conscious choices by 
patients.10 These decisions are based on patients’ 
beliefs about medicines in general that are affected by 
the experience of family and friends, culture, education, 
social circumstances, fears and anxieties and may be 
the result of an incomplete understanding of epilepsy 
and the proposed treatment. The result may be that 
patients are unsure that the benefits of AED treatment 
outweigh the perceived risks of taking medication. 11 In 
this study most common reason for non compliance was 
high cost of antiepileptic drugs (62.1%). (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antiepi-
leptic drugs (9.4%), freedom from fits (8.9%), deviation 
from prescription (6.4%) and Non Availability of drugs 
(5.9%). A survey undertaken by Neurologists (n=661) 
in the USA10 revealed that 71% of patients with 
epilepsy forgot to take their AED (anti-epileptic drug) at 
least once per month and it was evident that the chance 
of a patient missing a dose increased with the number 
of tablets prescribed. Of patients that missed a dose 
45% reported a seizure. Patients taking a larger number 
of tablets/capsules increased their odds of having a 
seizure after a missed dose by 43%. Similar results were 
reported in a recent UK study 12 which revealed that 
59% of epilepsy patients had poor compliance and that 
this was related to an increased frequency of seizures. A 
study in Germany13 measured post-ictal serum levels of 
anti-epileptic medications and confirmed that in at least 
44% of cases the seizure was related to poor compli-
ance. A review of 10,892 epilepsy patients in a USA 
managed care system 14 revealed that poor adherence 
was associated with a 11% increase in hospitalization 
and a 47% increase in emergency admissions and as a 
consequence there was significantly increased health-
care costs. It is evident that if patients’ seizures are not 
controlled by one AED there may be no point changing 
to another if the reason for lack of efficacy is non-
compliance. Studies have investigated a range of inter-
ventions, but improving compliance in chronic condi-
tions such as epilepsy is a complex task.15 Clinical 
guidelines provide detailed recommendations about the 
importance of ongoing counseling, education and 
support for people with epilepsy16, and it is also essen-
tial to ask about practical problems that may reduce 
compliance, including any difficulties in taking the medi-
cine, side-effects or inconvenient AED dosing. The 
number of daily doses is the most consistent predictor of 
noncompliance with AED treatment and an increased 
risk of seizure.10 The aim should be to move towards an 
easy-to-take once daily medication whenever possible. 
Opportunities to simplify the dosage of an AED are 
limited since the majority of these drugs must be taken 
twice or three times daily and the licensed indications of 
some once-daily drugs are limited. 
Conclusion
In this study, high cost of antiepileptic drugs was the 
most common reason for non compliance and non-
availability of drugs was the least common reason. 
While unemployment was the second common reason 
for non-compliance. These findings underscore the 
factors associated with and the impact of non-
adherence in adult patients with epilepsy. Targeted 
epilepsy management programs and communication 
strategies are necessary to improve adherence and to 
avoid the clinical consequences of poor adherence.
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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INTRODUCTION
In medicine, by the word compliance we mean how 
much a patient behaves in accordance with medical 
advice regarding medication usage, modification of 
lifestyle and follow up visits to the attending physician. 
With respect to drug therapy, compliance is defined as 
the degree of correspondence of the actual dosing 
history with the prescribed drug regimen.1 Epilepsy is 
one those chronic conditions where failure to comply 
with treatment regimen leads to two major conse-
quences: an unfavorable and unwanted health 
outcome for the patient and an increase in health care 
costs. Negative health outcomes include loss of seizure 
control with resultant injury, increased morbidity and 
even death. An increase in health care cost is attributed 
to an increase in physician office visits, emergency 
room care and/or hospitalizations, and a decrease in 
productivity (e.g., missing school and work).2 Studies 
regarding adherence have found four primary factors 
associated with medication non-adherence: patient-
related factors (e.g., socio-economic characteristics, 
and perceptions and beliefs), illness-related factors 
(e.g., severity of illness and frequency of symptoms), 
medication-related factors (e.g., number of daily doses, 
efficacy, and side effects), and physician-related factors 
(e.g., patient-physician relationship).3 Research regard-
ing patient adherence to AEDs has focused largely on 
the impact of the patient physician relationship on 
adherence and potential education programs intended 
to improve adherence. Findings suggest that patients 
tend to be more adherent when physicians have open 
dialogue regarding epilepsy and its treatments and 
when patients are comfortable speaking with their 
physician.4 Due to the paucity of published studies on 
non adherence among patients with epilepsy, this study 
investigates the factors associated with non-adherence 
to AEDs and help in taking possible measures to 
improve antiepileptic drug compliance and prevent 
consequences of uncontrolled seizures. The prevalence 
of epilepsy in Pakistan is about 9.99/1000. Highest 
prevalence is seen in people younger than 30 years of 
age. Higher prevalence is observed in rural population. 
Only 27.5% epileptic persons in urban areas and 1.9% 
in the rural areas were treated with antiepileptic drugs.3 
When treating epilepsy, the ideal is to achieve complete 
seizure control if compliant; up to 70 per cent of people 
with epilepsy can expect to become seizure free with 
optimal AED therapy.5 
Methods 
This was a cross-sectional study carried out at the 
Department of Neurology, Dow University of Health 
Sciences and Civil Hospital Karachi. All the patients 
with epilepsy attending Neurology outpatient Clinic 
between a period of six months extending from February 
2010 to August 2010 were analyzed and study group 
was selected according to the predetermined inclusion 
and exclusion criteria.  In addition to demographic data, 
factors responsible for non compliance were assessed 
with the help of a structured proforma designed specifi-
cally for this purpose. In this cross-sectional study, a 
total of 203 patients with epilepsy, attending Neurology 
Outpatient Clinic at Civil Hospital Karachi during a 
period of six months extending from August 2010 to 
February 2011 were included. Non probability, purpo-
sive sampling technique was applied. Detailed history 
was taken from each patient. A structured proformas 
was filled for each patient at the time of visit to note the 
factors that were responsible for non-compliance. 
Following is Patient Inclusion Criteria 
• Diagnosis of idiopathic epilepsy irrespective of the
 duration of disease and have been prescribed
 antiepileptic drug by a physician with a proper 
 prescription 
• Patients skipping at least one dose of antiepileptic
 drug in a week. 
• Or missing the dose infrequently but missing
 resulting in seizure.
• Age: 06 to 60 years either male or female. 
Patients with following criteria were excluded
• Patients with symptomatic epilepsy
• Diagnosed case of chronic renal or hepatic failure 
 or any other metabolic disorder that would have
 impaired the concentration of AED. 
• Patients who were given inadequate dosage or
 inadequate instructions by their physicians.
Data was analyzed on SPSS version 14.0. Frequencies 
and percentages were computed for qualitative 
variables, gender, age group, educational status and 
factors leading to non-compliance (e.g high cost, 
unemployment, kept on more than on drug, side 
effects, freedom from fits, deviation from prescription, 
non availability of drugs, personal belief-taboos and 
taking other medicines). Mean and standard deviation 
was computed for quantitative variables like age. Strati-
fication was done on age, gender and education status 
to see the effects on outcome.
Results
A total of 203 diagnosed cases of epilepsy were 
included in this study. Of 203 cases of epilepsy, 133 
(65.5%) patients were male and 70 (34.5%) female 




The mean age of patients attended Department of 
Neurology, Civil Hospital Karachi was 29.1 ±16.9 years 
and their age ranged from 6 years to 60 years. Majority 
83 (40.9%) of cases had age between 5 – 20 years. 
(Figure-1)
Education level of participants was also noted .The 
majority of patients were illiterate 101(49.8%), 82 
(40.4%) participants were educated up to matric, 18 
(8.9%) were intermediate and only 2 (1%) patients 
were graduate. (Table-2)





Most common reason for non compliance was high cost 
of antiepileptic drugs 126 (62.1%). Fifty eight (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antie-
pileptic drugs 19 (9.4%), freedom from fits 18 (8.9%), 
deviation from prescription 13 (6.4%) and Non Avail-
ability of drugs 12 (5.9%) (Table-3)
Factors  n (%)
High Cost 126 (62.1)
Unemployment 58 (28.6)
Kept on more than on drug 35 (17.2)
Side Effects 19 (9.4)
Freedom from fits 18 (8.9)
Deviation from Prescription 13 (6.4)
Non Availability of drugs 12 (5.9)
Personal belief-taboos 11 (5.4)
Taking other medicines 5 (2.5)
In male patients most dominant reason for poor drug 
compliance was unemployment 57 (98.3%), followed 
by high cost 90 (71.4%), freedom from fits 12(66.7%), 
side effects 11 (57.9%) and non availability of drugs 6 
(50%). (Table-4) 
Whereas in female patients the most prominent reason 
for poor drug compliance was personal belief –taboos 7 
(63.6%), followed by taking other medicines for other 
illness 3 (60%), deviation from prescription 8 (61.5%) 
and kept on more than one antiepileptic drug 18 
(51.4%). (Table-4)
When reasons for noncompliance were cross tabulated 
against different age groups, Unemployment (44.8%) 
was found most prominent reason of poor drug compli-
ance in age groups 21-40 and 41-60. Personal belief-
taboos (45.4%) was associated with younger age group 
5-20. (Table-5)
Factors  Age Group (Years)
 05-20 21-40 41-60
High Cost 51 (40.47%) 36 (28.5%) 3 9 
(30.9%)
Non Availability of drugs 4 (33.3%) 5 (41.6%) 
3 (25%)
Personal belief-taboos 5 (45.4%) 2 (18.1%) 
4 (36.3%)
Freedom from fits 5 (27.7%) 7 (38.8%) 
6 (33.3%)
Unemployment 6 (10.3%) 26 (44.8%) 2 6 
(44.8%)
Side Effects 15 (78.9%) 2 (10.5%) 2 
(10.5%)
Taking other medicines 0.0% 0.0% 100.0%
Kept on more than on drug 20 (57.1%) 6 
(17.1%) 9 (25.7%)
Deviation from Prescription 6 (46.1%) 5 
(38.4%) 2 (15.3%)
 
Factors associated to noncompliance were also 
analyzed against education level of patients. Non avail-
ability of antiepileptic drug 9 (75%) was the major 
cause of poor compliance in illiterate patients. Unem-
ployment 30 (51.7%) and high cost 61 (48.4%) were 















Non Availability of 
drugs 




Personal belief-ta s 



















Taking other medicines 

















Age Group (Years) 
















































0.0% 0.0% 100.0% 
Kept on more 


























Non Availability of 
drugs 
























Taking other medicines 




































































































































0 3 V O L .  1 0  ( 1 )  J A N   -   M A R C H   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
O R I G I N A L  A R T I C L E
Discussion
Compliance with a prescribed medicine regimen is a 
ubiquitous problem not confined to the treatment of 
asymptomatic conditions. Despite this, the poor compli-
ance in patients with epilepsy is somewhat surprising 
given that patients are aware of the serious conse-
quences in terms of seizures and even death. In this 
context it is important that we look for ways to improve 
epilepsy patients’ adherence to the prescribed medica-
tion as a way of improving outcome. There are many 
factors that influence compliance in people with 
epilepsy but the frequency, type and severity of seizures 
do not in themselves appear to influence compliance 
rates.6 Irregular requests for repeat AED prescriptions, 
lack of response to appropriate therapy and an increase 
in seizure frequency may indicate non-compliance. It is, 
however, difficult to identify all patients who do not 
comply with their AED therapy. Health professionals 
should therefore be alert to the potential for non-
compliance in all patients with epilepsy, enquiring non-
judgementally about medicine taking at each consulta-
tion and being prepared to support patients in complying 
with their treatment. In addition to the diagnosis of 
epilepsy in a considerable number of patients depres-
sive mood changes exist. In those patients rates of 
adherence is reduced and requires special strategies for 
continuous treatment.7 The patients can have poor 
compliance if they do not understand the importance of 
taking their medication, if they experience side effects, 
feel stigmatized by their condition, have difficulty in 
swallowing their medication or have multiple doses.8 
These issues can be multiplied if the patient is on multi-
ple medications for concomitant conditions. Age can 
also be a factor with compliance being particularly poor 
in teenagers.9 Although non-compliance in epilepsy may 
be unintentional, most non-compliance with AEDs is 
intentional and results from conscious choices by 
patients.10 These decisions are based on patients’ 
beliefs about medicines in general that are affected by 
the experience of family and friends, culture, education, 
social circumstances, fears and anxieties and may be 
the result of an incomplete understanding of epilepsy 
and the proposed treatment. The result may be that 
patients are unsure that the benefits of AED treatment 
outweigh the perceived risks of taking medication. 11 In 
this study most common reason for non compliance was 
high cost of antiepileptic drugs (62.1%). (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antiepi-
leptic drugs (9.4%), freedom from fits (8.9%), deviation 
from prescription (6.4%) and Non Availability of drugs 
(5.9%). A survey undertaken by Neurologists (n=661) 
in the USA10 revealed that 71% of patients with 
epilepsy forgot to take their AED (anti-epileptic drug) at 
least once per month and it was evident that the chance 
of a patient missing a dose increased with the number 
of tablets prescribed. Of patients that missed a dose 
45% reported a seizure. Patients taking a larger number 
of tablets/capsules increased their odds of having a 
seizure after a missed dose by 43%. Similar results were 
reported in a recent UK study 12 which revealed that 
59% of epilepsy patients had poor compliance and that 
this was related to an increased frequency of seizures. A 
study in Germany13 measured post-ictal serum levels of 
anti-epileptic medications and confirmed that in at least 
44% of cases the seizure was related to poor compli-
ance. A review of 10,892 epilepsy patients in a USA 
managed care system 14 revealed that poor adherence 
was associated with a 11% increase in hospitalization 
and a 47% increase in emergency admissions and as a 
consequence there was significantly increased health-
care costs. It is evident that if patients’ seizures are not 
controlled by one AED there may be no point changing 
to another if the reason for lack of efficacy is non-
compliance. Studies have investigated a range of inter-
ventions, but improving compliance in chronic condi-
tions such as epilepsy is a complex task.15 Clinical 
guidelines provide detailed recommendations about the 
importance of ongoing counseling, education and 
support for people with epilepsy16, and it is also essen-
tial to ask about practical problems that may reduce 
compliance, including any difficulties in taking the medi-
cine, side-effects or inconvenient AED dosing. The 
number of daily doses is the most consistent predictor of 
noncompliance with AED treatment and an increased 
risk of seizure.10 The aim should be to move towards an 
easy-to-take once daily medication whenever possible. 
Opportunities to simplify the dosage of an AED are 
limited since the majority of these drugs must be taken 
twice or three times daily and the licensed indications of 
some once-daily drugs are limited. 
Conclusion
In this study, high cost of antiepileptic drugs was the 
most common reason for non compliance and non-
availability of drugs was the least common reason. 
While unemployment was the second common reason 
for non-compliance. These findings underscore the 
factors associated with and the impact of non-
adherence in adult patients with epilepsy. Targeted 
epilepsy management programs and communication 
strategies are necessary to improve adherence and to 
avoid the clinical consequences of poor adherence.
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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INTRODUCTION
In medicine, by the word compliance we mean how 
much a patient behaves in accordance with medical 
advice regarding medication usage, modification of 
lifestyle and follow up visits to the attending physician. 
With respect to drug therapy, compliance is defined as 
the degree of correspondence of the actual dosing 
history with the prescribed drug regimen.1 Epilepsy is 
one those chronic conditions where failure to comply 
with treatment regimen leads to two major conse-
quences: an unfavorable and unwanted health 
outcome for the patient and an increase in health care 
costs. Negative health outcomes include loss of seizure 
control with resultant injury, increased morbidity and 
even death. An increase in health care cost is attributed 
to an increase in physician office visits, emergency 
room care and/or hospitalizations, and a decrease in 
productivity (e.g., missing school and work).2 Studies 
regarding adherence have found four primary factors 
associated with medication non-adherence: patient-
related factors (e.g., socio-economic characteristics, 
and perceptions and beliefs), illness-related factors 
(e.g., severity of illness and frequency of symptoms), 
medication-related factors (e.g., number of daily doses, 
efficacy, and side effects), and physician-related factors 
(e.g., patient-physician relationship).3 Research regard-
ing patient adherence to AEDs has focused largely on 
the impact of the patient physician relationship on 
adherence and potential education programs intended 
to improve adherence. Findings suggest that patients 
tend to be more adherent when physicians have open 
dialogue regarding epilepsy and its treatments and 
when patients are comfortable speaking with their 
physician.4 Due to the paucity of published studies on 
non adherence among patients with epilepsy, this study 
investigates the factors associated with non-adherence 
to AEDs and help in taking possible measures to 
improve antiepileptic drug compliance and prevent 
consequences of uncontrolled seizures. The prevalence 
of epilepsy in Pakistan is about 9.99/1000. Highest 
prevalence is seen in people younger than 30 years of 
age. Higher prevalence is observed in rural population. 
Only 27.5% epileptic persons in urban areas and 1.9% 
in the rural areas were treated with antiepileptic drugs.3 
When treating epilepsy, the ideal is to achieve complete 
seizure control if compliant; up to 70 per cent of people 
with epilepsy can expect to become seizure free with 
optimal AED therapy.5 
Methods 
This was a cross-sectional study carried out at the 
Department of Neurology, Dow University of Health 
Sciences and Civil Hospital Karachi. All the patients 
with epilepsy attending Neurology outpatient Clinic 
between a period of six months extending from February 
2010 to August 2010 were analyzed and study group 
was selected according to the predetermined inclusion 
and exclusion criteria.  In addition to demographic data, 
factors responsible for non compliance were assessed 
with the help of a structured proforma designed specifi-
cally for this purpose. In this cross-sectional study, a 
total of 203 patients with epilepsy, attending Neurology 
Outpatient Clinic at Civil Hospital Karachi during a 
period of six months extending from August 2010 to 
February 2011 were included. Non probability, purpo-
sive sampling technique was applied. Detailed history 
was taken from each patient. A structured proformas 
was filled for each patient at the time of visit to note the 
factors that were responsible for non-compliance. 
Following is Patient Inclusion Criteria 
• Diagnosis of idiopathic epilepsy irrespective of the
 duration of disease and have been prescribed
 antiepileptic drug by a physician with a proper 
 prescription 
• Patients skipping at least one dose of antiepileptic
 drug in a week. 
• Or missing the dose infrequently but missing
 resulting in seizure.
• Age: 06 to 60 years either male or female. 
Patients with following criteria were excluded
• Patients with symptomatic epilepsy
• Diagnosed case of chronic renal or hepatic failure 
 or any other metabolic disorder that would have
 impaired the concentration of AED. 
• Patients who were given inadequate dosage or
 inadequate instructions by their physicians.
Data was analyzed on SPSS version 14.0. Frequencies 
and percentages were computed for qualitative 
variables, gender, age group, educational status and 
factors leading to non-compliance (e.g high cost, 
unemployment, kept on more than on drug, side 
effects, freedom from fits, deviation from prescription, 
non availability of drugs, personal belief-taboos and 
taking other medicines). Mean and standard deviation 
was computed for quantitative variables like age. Strati-
fication was done on age, gender and education status 
to see the effects on outcome.
Results
A total of 203 diagnosed cases of epilepsy were 
included in this study. Of 203 cases of epilepsy, 133 
(65.5%) patients were male and 70 (34.5%) female 




The mean age of patients attended Department of 
Neurology, Civil Hospital Karachi was 29.1 ±16.9 years 
and their age ranged from 6 years to 60 years. Majority 
83 (40.9%) of cases had age between 5 – 20 years. 
(Figure-1)
Education level of participants was also noted .The 
majority of patients were illiterate 101(49.8%), 82 
(40.4%) participants were educated up to matric, 18 
(8.9%) were intermediate and only 2 (1%) patients 
were graduate. (Table-2)





Most common reason for non compliance was high cost 
of antiepileptic drugs 126 (62.1%). Fifty eight (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antie-
pileptic drugs 19 (9.4%), freedom from fits 18 (8.9%), 
deviation from prescription 13 (6.4%) and Non Avail-
ability of drugs 12 (5.9%) (Table-3)
Factors  n (%)
High Cost 126 (62.1)
Unemployment 58 (28.6)
Kept on more than on drug 35 (17.2)
Side Effects 19 (9.4)
Freedom from fits 18 (8.9)
Deviation from Prescription 13 (6.4)
Non Availability of drugs 12 (5.9)
Personal belief-taboos 11 (5.4)
Taking other medicines 5 (2.5)
In male patients most dominant reason for poor drug 
compliance was unemployment 57 (98.3%), followed 
by high cost 90 (71.4%), freedom from fits 12(66.7%), 
side effects 11 (57.9%) and non availability of drugs 6 
(50%). (Table-4) 
Whereas in female patients the most prominent reason 
for poor drug compliance was personal belief –taboos 7 
(63.6%), followed by taking other medicines for other 
illness 3 (60%), deviation from prescription 8 (61.5%) 
and kept on more than one antiepileptic drug 18 
(51.4%). (Table-4)
When reasons for noncompliance were cross tabulated 
against different age groups, Unemployment (44.8%) 
was found most prominent reason of poor drug compli-
ance in age groups 21-40 and 41-60. Personal belief-
taboos (45.4%) was associated with younger age group 
5-20. (Table-5)
Factors  Age Group (Years)
 05-20 21-40 41-60
High Cost 51 (40.47%) 36 (28.5%) 3 9 
(30.9%)
Non Availability of drugs 4 (33.3%) 5 (41.6%) 
3 (25%)
Personal belief-taboos 5 (45.4%) 2 (18.1%) 
4 (36.3%)
Freedom from fits 5 (27.7%) 7 (38.8%) 
6 (33.3%)
Unemployment 6 (10.3%) 26 (44.8%) 2 6 
(44.8%)
Side Effects 15 (78.9%) 2 (10.5%) 2 
(10.5%)
Taking other medicines 0.0% 0.0% 100.0%
Kept on more than on drug 20 (57.1%) 6 
(17.1%) 9 (25.7%)
Deviation from Prescription 6 (46.1%) 5 
(38.4%) 2 (15.3%)
 
Factors associated to noncompliance were also 
analyzed against education level of patients. Non avail-
ability of antiepileptic drug 9 (75%) was the major 
cause of poor compliance in illiterate patients. Unem-
ployment 30 (51.7%) and high cost 61 (48.4%) were 





Compliance with a prescribed medicine regimen is a 
ubiquitous problem not confined to the treatment of 
asymptomatic conditions. Despite this, the poor compli-
ance in patients with epilepsy is somewhat surprising 
given that patients are aware of the serious conse-
quences in terms of seizures and even death. In this 
context it is important that we look for ways to improve 
epilepsy patients’ adherence to the prescribed medica-
tion as a way of improving outcome. There are many 
factors that influence compliance in people with 
epilepsy but the frequency, type and severity of seizures 
do not in themselves appear to influence compliance 
rates.6 Irregular requests for repeat AED prescriptions, 
lack of response to appropriate therapy and an increase 
in seizure frequency may indicate non-compliance. It is, 
however, difficult to identify all patients who do not 
comply with their AED therapy. Health professionals 
should therefore be alert to the potential for non-
compliance in all patients with epilepsy, enquiring non-
judgementally about medicine taking at each consulta-
tion and being prepared to support patients in complying 
with their treatment. In addition to the diagnosis of 
epilepsy in a considerable number of patients depres-
sive mood changes exist. In those patients rates of 
adherence is reduced and requires special strategies for 
continuous treatment.7 The patients can have poor 
compliance if they do not understand the importance of 
taking their medication, if they experience side effects, 
feel stigmatized by their condition, have difficulty in 
swallowing their medication or have multiple doses.8 
These issues can be multiplied if the patient is on multi-
ple medications for concomitant conditions. Age can 
also be a factor with compliance being particularly poor 
in teenagers.9 Although non-compliance in epilepsy may 
be unintentional, most non-compliance with AEDs is 
intentional and results from conscious choices by 
patients.10 These decisions are based on patients’ 
beliefs about medicines in general that are affected by 
the experience of family and friends, culture, education, 
social circumstances, fears and anxieties and may be 
the result of an incomplete understanding of epilepsy 
and the proposed treatment. The result may be that 
patients are unsure that the benefits of AED treatment 
outweigh the perceived risks of taking medication. 11 In 
this study most common reason for non compliance was 
high cost of antiepileptic drugs (62.1%). (28.6%) 
patients had poor drug compliance because they were 
not employed consequently do not have enough money 
to buy medicine, 35 (17.2%) patients skipped from 
timely dose because they were prescribed more than 
one antiepileptic drug followed by side effects of antiepi-
leptic drugs (9.4%), freedom from fits (8.9%), deviation 
from prescription (6.4%) and Non Availability of drugs 
(5.9%). A survey undertaken by Neurologists (n=661) 
in the USA10 revealed that 71% of patients with 
epilepsy forgot to take their AED (anti-epileptic drug) at 
least once per month and it was evident that the chance 
of a patient missing a dose increased with the number 
of tablets prescribed. Of patients that missed a dose 
45% reported a seizure. Patients taking a larger number 
of tablets/capsules increased their odds of having a 
seizure after a missed dose by 43%. Similar results were 
reported in a recent UK study 12 which revealed that 
59% of epilepsy patients had poor compliance and that 
this was related to an increased frequency of seizures. A 
study in Germany13 measured post-ictal serum levels of 
anti-epileptic medications and confirmed that in at least 
44% of cases the seizure was related to poor compli-
ance. A review of 10,892 epilepsy patients in a USA 
managed care system 14 revealed that poor adherence 
was associated with a 11% increase in hospitalization 
and a 47% increase in emergency admissions and as a 
consequence there was significantly increased health-
care costs. It is evident that if patients’ seizures are not 
controlled by one AED there may be no point changing 
to another if the reason for lack of efficacy is non-
compliance. Studies have investigated a range of inter-
ventions, but improving compliance in chronic condi-
tions such as epilepsy is a complex task.15 Clinical 
guidelines provide detailed recommendations about the 
importance of ongoing counseling, education and 
support for people with epilepsy16, and it is also essen-
tial to ask about practical problems that may reduce 
compliance, including any difficulties in taking the medi-
cine, side-effects or inconvenient AED dosing. The 
number of daily doses is the most consistent predictor of 
noncompliance with AED treatment and an increased 
risk of seizure.10 The aim should be to move towards an 
easy-to-take once daily medication whenever possible. 
Opportunities to simplify the dosage of an AED are 
limited since the majority of these drugs must be taken 
twice or three times daily and the licensed indications of 
some once-daily drugs are limited. 
Conclusion
In this study, high cost of antiepileptic drugs was the 
most common reason for non compliance and non-
availability of drugs was the least common reason. 
While unemployment was the second common reason 
for non-compliance. These findings underscore the 
factors associated with and the impact of non-
adherence in adult patients with epilepsy. Targeted 
epilepsy management programs and communication 
strategies are necessary to improve adherence and to 
avoid the clinical consequences of poor adherence.
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INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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